Stockscreener 앱 받기
1.31
0.77%
0.01
시간 외 거래:
1.34
0.03
+2.29%
전일 마감가:
$1.30
열려 있는:
$1.29
하루 거래량:
123.59K
Relative Volume:
0.18
시가총액:
$81.11M
수익:
$248.00K
순이익/손실:
$-149.34M
주가수익비율:
-0.538
EPS:
-2.4348
순현금흐름:
$-128.71M
1주 성능:
-3.68%
1개월 성능:
-2.96%
6개월 성능:
-16.56%
1년 성능:
-10.27%
1일 변동 폭
$1.29
$1.33
1주일 범위
$1.265
$1.37
52주 변동 폭
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
명칭
Pliant Therapeutics Inc
전화
650-481-6770
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.31 | 80.49M | 248.00K | -149.34M | -128.71M | -2.4348 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-03-04 | 재개 | Cantor Fitzgerald | Neutral |
| 2025-03-04 | 다운그레이드 | Needham | Buy → Hold |
| 2025-03-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-02-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-05-18 | 개시 | Canaccord Genuity | Buy |
| 2023-04-13 | 개시 | Robert W. Baird | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-07 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Outperform |
| 2022-05-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-03 | 개시 | H.C. Wainwright | Buy |
| 2021-04-20 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Cowen | Outperform |
| 2020-06-29 | 개시 | Needham | Buy |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
모두보기
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
Pliant Therapeutics (NASDAQ:PLRX) Shares Up 1.6%Should You Buy? - MarketBeat
If You Invested $1,000 in Pliant Therapeutics, Inc. (PLRX) - Stock Titan
Bull Run: Is Pliant Therapeutics Inc subject to activist investor interest2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
Inflation Data: Is Pliant Therapeutics Inc still a buy after recent gainsPortfolio Update Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
[EFFECT] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan
Pliant Therapeutics, Inc. (PLRX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Live Pliant Therapeutics, Inc. (PLRX) Technical Analysis - Traders Union
Pliant Therapeutics (PLRX) Stock Analysis Report | Financials & Insights - Benzinga Japan
PLRX PE Ratio & Valuation, Is PLRX Overvalued - Intellectia AI
Pliant Therapeutics, Inc. (PLRX) Stock Price Prediction for 2026, 2030-2040 - tradersunion.com
Pliant Therapeutics Launches New $50 Million ATM Program - TipRanks
Pliant Therapeutics (NASDAQ: PLRX) files $300M shelf; $50M ATM with Leerink - Stock Titan
Pliant Therapeutics launches $50M at-the-market equity program, terminates prior sales agreement - TradingView
Pliant Therapeutics (NASDAQ: PLRX) shifts to new $50M at-the-market program - Stock Titan
Quarterly Recap: Is Pliant Therapeutics Inc subject to activist investor interestPortfolio Gains Summary & Comprehensive Market Scan Reports - baoquankhu1.vn
Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN
Sentiment Recap: Is Pliant Therapeutics Inc still a buy after recent gains2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Analyst Calls: Is Pliant Therapeutics Inc benefiting from interest rate changesWeekly Profit Recap & AI Enhanced Trading Signals - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR By Investing.com - Investing.com South Africa
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR - Investing.com Australia
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Investing News Network
AACR 2026 to feature Pliant Therapeutics Phase 1 PLN-101095 results at major symposium - Traders Union
Pliant Therapeutics Announces Upcoming Presentation Of Phase 1 Clinical Trial Of PLN-101095 In Patients With Solid Tumors At The 2026 Aacr Annual Meeting - TradingView
Pliant Therapeutics Announces Upcoming Presentation of - GlobeNewswire
Clinical Progress and Disclosure Timeline: Biopharmaceutical company Pliant Therapeutics (NASDAQ: PLRX) announced that Phase I clinical trial data for its solid tumor candidate drug Pln-101095 will be officially released at the 2026 American Association f - Bitget
Portfolio Shifts: Is Pliant Therapeutics Inc benefiting from interest rate changes2026 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
Prosight Management Cuts Stake in Pliant Therapeutics - National Today
Prosight Management LP Has $30,000 Position in Pliant Therapeutics, Inc. $PLRX - MarketBeat
How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance - The Globe and Mail
Oppenheimer Remains a Hold on Pliant Therapeutics (PLRX) - The Globe and Mail
Pliant Therapeutics (PLRX): Canaccord Genuity Adjusts Price Targ - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price - MarketBeat
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK) - The Globe and Mail
Pliant Therapeutics (PLRX) Analyst Rating Update: Piper Sandler Lowers Price Target | PLRX Stock News - GuruFocus
Piper Sandler cuts Pliant Therapeutics stock price target to $3 By Investing.com - Investing.com Canada
Pliant Therapeutics Reports Q4 2025 Financial Results and Corporate Update – 8-K Filing Summary - Minichart
Pliant Therapeutics 2025 Annual Report: Business Overview, Risks, Regulatory Environment, and Competitive Landscape - Minichart
Pliant Therapeutics (PLRX) Advances Oncology Drug Development - GuruFocus
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
PLRX: Net loss improved to $149.3M as focus shifted to PLN-101095; $192.4M cash on hand - TradingView
Pliant Therapeutics 10‑K — No Revenue; Net Loss $2.43 EPS on $149.3M Net Loss - TradingView
PLRX: PLN-101095 advances to Phase 1b after strong Phase 1 data; net loss narrows on lower expenses - TradingView
Oncology data and cost cuts reshape Pliant Therapeutics (NASDAQ: PLRX) - Stock Titan
BRIEF-Pliant Therapeutics Q4 Net Income USD -23.577 Million - TradingView
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - ChartMill
Market Rankings: Is Pliant Therapeutics Inc stock good for income investorsQuarterly Profit Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Lyell Immunopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration - The Globe and Mail
Pliant Therapeutics Inc (PLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):